%0 Journal Article
%T Interleukin 23 versus interleukin 12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network.
%A Tsai SHL
%A Yang CY
%A Huo AP
%A Wei JC
%J J Am Acad Dermatol
%V 0
%N 0
%D 2024 Jul 28
%M 39079603
%F 15.487
%R 10.1016/j.jaad.2024.07.1473
%X <B>BACKGROUND: </B>Managing psoriasis (PsO) and its comorbidities, particularly psoriatic arthritis, often involves using interleukin (IL)-23 and IL-12/23 inhibitors. However, the comparative risk of these treatments still needs to be explored.<BR><B>OBJECTIVE: </B>This study evaluates the risk of developing psoriatic arthritis in patients treated with IL-23 inhibitors compared to IL-12/23 inhibitors.<BR><B>METHODS: </B>This retrospective cohort study utilized data from the TriNetX, including adult patients diagnosed with PsO. Patients with IL-23 or IL-12/23 inhibitors treatment were included and propensity score matched. The primary outcome was the incidence of psoriatic arthritis (PsA), analyzed using a Cox regression hazard model and Kaplan-Meier estimates.<BR><B>RESULTS: </B>The study included matched cohorts of patients treated with IL-23 inhibitors (n = 2273) and IL-12/23 inhibitors (n = 2995). Cox regression analysis revealed no significant difference in the cumulative incidence of PsA between the IL-23i and IL-12/23i cohorts (P = .812). Kaplan-Meier estimates confirmed similar cumulative incidences of arthropathic PsO in both cohorts over the study period.<BR><B>CONCLUSIONS: </B>Long-term follow-up studies are required to understand more of the effects of these interleukin inhibitors.<BR><B>CONCLUSIONS: </B>No significant difference but a numerically lower risk of psoriatic arthritis in PsO patients treated with IL-23 inhibitors than with IL-12/23 inhibitors was found, underscoring their comparable efficacy in PsO management and follow-up.